Should I Buy JANX? JANX 2026 Analysis

Should You Buy Janux Therapeutics Inc (JANX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

13.070

1 Day change

7.31%

52 Week Range

41.560

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: price is still in a bearish trend, sitting below near-term support, with heavy insider/hedge-fund selling and fresh analyst skepticism.
Best read today is “avoid chasing” until it reclaims key levels (~$14.33 pivot) or shows a clear reversal; otherwise risk of a flush toward ~$12.98 support remains.
Intellectia Proprietary Trading Signals
AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.
Politician/congress activity: no recent congress trading data available (no influential-figure confirmation bid).

Technical Analysis

Trend/MAs: Bearish structure (SMA_200 > SMA_20 > SMA_5) = prevailing downtrend still intact.
RSI(6) ~32.9: nearing oversold territory, which can support a short-term bounce, but it’s not a confirmed reversal by itself.
MACD histogram +0.175 but “positively contracting”: upside momentum is fading; rebound attempts may stall without a catalyst.
Key levels: Current ~13.33 is below S1 (13.498) and below Pivot (14.331) → technically weak. Next support S2 ~12.984. Resistance levels to clear: 14.33 then 15.16.
Pattern-based odds (provided): slight downside next day (-0.09%) but modest upside bias over 1W (+0.61%) and 1M (+6.64%); timing still looks unfavorable given the broken support.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Open-interest put/call 0.49 is call-heavy (more bullish longer positioning), but today’s volume put/call 0.9 is close to balanced (not an aggressive dip-buying stampede).
Volatility: IV30 ~69.4 vs HV ~51.5 → options imply larger moves than recent realized; however IV percentile ~10 and IV rank ~15.8 suggest IV is low versus its own history (options relatively “cheap” vs recent extremes).
Activity: Today’s volume 318 is far below 5D/10D averages (~~1351/~~1151), implying muted conviction ahead of earnings.

Technical Summary

Sell

Buy

Positive Catalysts

can spark a reflex bounce.
on 2026-02-26 after hours can act as a volatility catalyst.

Neutral/Negative Catalysts

to Hold with PT cut to $12 highlights “material platform risk,” durability uncertainty (JANX007), and lack of incremental data (JANX008).
and below pivot (14.
increases probability of further downside toward ~12.
- Flow/sentiment: Hedge funds are selling (selling amount +575.67% QoQ) and insiders are selling (+137.72% MoM) — strong negative signal for near-term demand.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $10.0M, up +2177.9% YoY (sharp increase, likely milestone/collab-driven rather than recurring product revenue).
Profitability: Net income -24.313M (worse by -13.35% YoY), EPS -0.39 (worse by -23.53% YoY) → losses still expanding.
Gross margin: 100% (typical for milestone/licensing revenue; doesn’t yet indicate scaled commercial profitability).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Trend: clear negative drift in the last ~2 months — repeated price-target cuts across the board and a major downgrade.
Key recent change: Clear Street (2026-01-20) downgraded to Hold from Buy; PT slashed to $12 from $32, citing durability/data uncertainty and platform risk.
Other firms: Piper, Barclays, Stifel, BofA and others cut targets (generally still Buy/Overweight), reflecting tempered expectations and pushed-out timelines.
Wall Street “pros” view: platform could still be valuable if durability/clinical clarity improves (some see selloff as overdone).
Wall Street “cons” view: execution risk is elevated now (durability questions, competitive pressure, unclear path/timelines), which is consistent with the downgrade, insider selling, and the stock’s weak chart.

16 Analyst Rating

Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 55.25 USD with a low forecast of 25 USD and a high forecast of 150 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

1 Hold

0 Sell

Strong Buy

Current: 12.180

Low

Averages

55.25

High

150

Current: 12.180

Low

Averages

55.25

High

150

Clear Street

Buy -> Hold

downgrade

$32 -> $12

AI Analysis

2026-01-20

Reason

Clear Street

Price Target

$32 -> $12

AI Analysis

2026-01-20

downgrade

Buy -> Hold

Reason

Clear Street downgraded Janux Therapeutics to Hold from Buy with a price target of $12, down from $32. The firm says the the absence of clear durability signals from JANX007 and the lack of incremental data from JANX008 "introduce material platform risk." Janux faces rising competitive momentum and an undefined path for JANX007, which elevates its execution risk, the analyst tells investors in a research note.

Piper Sandler

Kelsey Goodwin

Overweight

downgrade

$42 -> $30

2026-01-16

Reason

Piper Sandler

Kelsey Goodwin

Price Target

$42 -> $30

2026-01-16

downgrade

Overweight

Reason

Piper Sandler analyst Kelsey Goodwin lowered the firm's price target on Janux Therapeutics to $30 from $42 and keeps an Overweight rating on the shares. Following a flurry of updates from companies across its coverage, the firm updating its 2026 Catalyst Tracker, as well as several models and price targets.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JANX

Unlock Now

JANX Should I Buy

JANX Should I Buy

Should You Buy Janux Therapeutics Inc (JANX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch